Literature DB >> 12968982

Do alterations of endogenous angiotensin II levels regulate erythropoietin production in humans?

S Freudenthaler1, P Benöhr, A Grenz, T Selzer, T Schmidt, K Mörike, H Osswald, C H Gleiter.   

Abstract

AIMS: Recent evidence suggests a potential role of angiotensin II in the physiological regulation of erythropoietin (Epo) production. While the administration of exogenous angiotensin II (AII) has been used so far to study its effects, the role of endogenous AII has remained unclear.
METHODS: To alter endogenous AII in humans experimentally we used furosemide bolus injection as a short-term (study 1) and dietary salt as a long-term modulator (study 2). In an open crossover design, 12 healthy male volunteers received furosemide (F) 0.5 mg kg(-1) intravenously or placebo (P) in random order (study 1). With the same design, 12 volunteers received high-salt (HS), normal-salt (NS) and low-salt (LS) diet (study 2). Plasma renin activity (PRA) was analysed along with AII. Inulin and paraaminohippurate (PAH) clearances were used to indicate glomerular filtration rate (GFR) and renal plasma flow (RPF), respectively.
RESULTS: While F stimulated AII and PRA and decreased GFR and RPF significantly, no concomitant alteration of Epo was observed [AUCEpo: placebo 5709 +/- 243 (% of baseline x h), furosemide: 5833 +/- 255 (% of baseline x h); 95% confidence interval (CI) -608.4, 856.0; P = 0.73]. F decreased GFR (from 103.6 +/- 4.0 to 90.6 +/- 4.8 ml min(-1) 1(-1) 73 m-2; 95% CI 1.1, 24.9; P < 0.05), but not RPF (study 1). Correspondingly, LS stimulated and HS decreased AII and PRA significantly. HS increased GFR and RPF. Again, Epo concentrations were not affected (AUCEpo: normal sodium 44 +/- 6.7 mIU x day ml(-1), low sodium 39 +/- 2.4 mIU x day ml(-1), high sodium 48.5 +/- 6.1 mIU x day ml(-1); normal salt/low salt 95% CI -11.9, 21.9, P = 0.54; normal salt/high salt 95% CI -14.4, 23.3, P = 0.63; study 2).
CONCLUSIONS: We conclude that, at least in the physiological setting in healthy volunteers, increased concentrations of endogenous AII may not be a major factor of Epo regulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12968982      PMCID: PMC1884363          DOI: 10.1046/j.1365-2125.2003.01894.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

1.  Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers.

Authors:  M C Pratt; N J Lewis-Barned; R J Walker; R R Bailey; B I Shand; J Livesey
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 2.  Posttransplant erythrocytosis: a model for the investigation of the pharmacological control of renal erythropoietin production?

Authors:  C H Gleiter
Journal:  Int J Clin Pharmacol Ther       Date:  1996-11       Impact factor: 1.366

3.  Erythropoietin production in healthy volunteers subjected to controlled haemorrhage: evidence against a major role for adenosine.

Authors:  C H Gleiter; S Freudenthaler; U Delabar; K U Eckardt; B Mühlbauer; U Gundert-Remy; H Osswald
Journal:  Br J Clin Pharmacol       Date:  1996-12       Impact factor: 4.335

4.  Efficacy of captopril on posttransplant erythrocytosis. Long-term follow-up.

Authors:  J V Torregrosa; J M Campistol; M Montesinos; A G Rogada; F Oppenheimer; J Andreu
Journal:  Transplantation       Date:  1994-08-15       Impact factor: 4.939

5.  Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis.

Authors:  B A Julian; R S Gaston; C V Barker; G Krystal; A G Diethelm; J J Curtis
Journal:  Kidney Int       Date:  1994-11       Impact factor: 10.612

6.  Response of urinary angiotensin to challenges of the renin-angiotensin system.

Authors:  P Boer; P F Vos; H A Koomans; A J Rabelink; J J Beutler; E J Dorhout Mees
Journal:  Clin Chim Acta       Date:  1991-06-14       Impact factor: 3.786

7.  Dietary salt intake modulates angiotensin II type 1 receptor gene expression.

Authors:  C Schmid; H Castrop; J Reitbauer; R Della Bruna; A Kurtz
Journal:  Hypertension       Date:  1997-04       Impact factor: 10.190

8.  Effect of captopril on the renal veno-arterial gradient of erythropoietin and oxygen in unilateral renal artery disease.

Authors:  J D Jensen; H Eiskjaer; B Madsen; M Egeblad; C B Nielsen; E B Pedersen
Journal:  Scand J Clin Lab Invest       Date:  1993-12       Impact factor: 1.713

9.  Endogenous erythropoietin and salt sensitivity of blood pressure in patients with essential hypertension.

Authors:  S Naomi; T Umeda; T Iwaoka; J Yamauchi; Y Ideguchi; Y Fujimoto; H Tokunaga; T Sato
Journal:  Am J Hypertens       Date:  1993-01       Impact factor: 2.689

10.  No acute change of serum erythropoietin in response to hypocalcemia or antihypertensive agents in uremic patients.

Authors:  P Ureña; L Bererhi; S Houhou; F Bournerias; K U Eckardt; A Kurtz; T B Drüeke
Journal:  Nephron       Date:  1995       Impact factor: 2.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.